Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer

Current Opinion in Oncology
Haven R Garber, Jennifer K Litton

Abstract

Poly(ADP-ribose) polymerase (PARP) inhibitors were recently approved for the treatment of patients with BRCA1 or BRCA2 germline pathogenic variants and metastatic breast cancer. PARP inhibitors have also demonstrated activity in early stage breast cancer, and this review discusses completed and ongoing trials of PARP inhibitors in the neoadjuvant and adjuvant setting. A recent phase II trial of neoadjuvant talazoparib monotherapy in patients with BRCA1 or BRCA2 germline pathogenic variants and early stage breast cancer demonstrated a pathological complete response in 10/19 (53%) patients. Previous trials of PARP inhibition in early stage breast cancer included the I-SPY-2 and BrighTNess trials, which ultimately failed to show a benefit for adding the PARP inhibitor veliparib to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. Investigators are building on these results by designing novel clinical trials for patients with BRCA1/2-deficient tumors and/or triple-negative breast cancer. The OlympiAD and EMBRACA trials that led to the recent approval of PARP inhibitors for metastatic breast cancer patients with BRCA1/2 germline pathogenic variants are practice changing. Investigators are now working ...Continue Reading

References

Nov 18, 2004·Journal of the National Cancer Institute·Richard D KennedyD Paul Harkin
Sep 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Deann P AtchleyBanu K Arun
Jan 7, 2011·The New England Journal of Medicine·Joyce O'ShaughnessyCharles Bradley
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Dec 1, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xuesong LiuAlexander R Shoemaker
Jan 20, 2012·Nature·Christopher J Lord, Alan Ashworth
Feb 1, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anand G PatelScott H Kaufmann
Mar 1, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Arun RajanGiuseppe Giaccone
Mar 29, 2012·The New England Journal of Medicine·Jonathan LedermannUrsula Matulonis
Nov 3, 2012·Cancer Research·Junko MuraiYves Pommier
Dec 21, 2013·Molecular Cancer Therapeutics·Junko MuraiYves Pommier
Feb 21, 2014·Nature Communications·Guang PengShiaw-Yih Lin
May 16, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BalmañaJ E Garber
Aug 19, 2014·Breast Cancer Research and Treatment·T ByrskiS A Narod
Oct 24, 2014·Annual Review of Medicine·Christopher J LordAlan Ashworth
Jan 8, 2015·The New England Journal of Medicine·Sara M TolaneyEric P Winer
Jun 9, 2015·Expert Opinion on Drug Safety·Stephanie LheureuxAmit M Oza
Oct 29, 2015·The New England Journal of Medicine·Joaquin MateoJohann S de Bono
Jan 9, 2016·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jan 19, 2016·Nature Reviews. Cancer·Christopher J Lord, Alan Ashworth
Mar 31, 2016·British Journal of Cancer·Jessica S BrownTimothy A Yap
May 4, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J A Ledermann
Oct 19, 2016·Nature Reviews. Clinical Oncology·Giampaolo BianchiniLuca Gianni
Jul 15, 2016·The New England Journal of Medicine·Hope S RugoUNKNOWN I-SPY 2 Investigators
Dec 14, 2016·Nature Reviews. Clinical Oncology·Angela GeorgeSusana Banerjee
Mar 14, 2017·Nature Medicine·Helen DaviesSerena Nik-Zainal
May 12, 2017·Therapeutic Advances in Medical Oncology·Tarra Evans, Ursula Matulonis
Jun 6, 2017·The New England Journal of Medicine·Mark RobsonPierfranco Conte
Aug 10, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mallika S DhawanPamela N Munster
Mar 9, 2018·BMC Cancer·Christoph EngelUNKNOWN German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC)

❮ Previous
Next ❯

Citations

Aug 31, 2019·Expert Review of Anticancer Therapy·Carolyn PiccininRaymond H Kim
Mar 31, 2021·Clinical Breast Cancer·Reshma MahtaniUNKNOWN Breast Cancer Therapy Expert Group (BCTEG)

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

Clinical Advances in Hematology & Oncology : H&O
Judy E Garber
Current Breast Cancer Reports
Shaveta Vinayak, James M Ford
Expert Opinion on Emerging Drugs
Marie RobertMario Campone
© 2022 Meta ULC. All rights reserved